GlaxoSmithKline PLC (GSK): Price and Financial Metrics
GlaxoSmithKline PLC (GSK)
Today's Latest Price: $37.89 USD
Updated Mar 31 8:04pm
Add GSK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
GSK Stock Summary
- GSK has a higher market value than 98.53% of US stocks; more precisely, its current market capitalization is $91,512,737,927.
- Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.17% of US equities in our set.
- The volatility of Glaxosmithkline Plc's share price is greater than that of just 6.78% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Glaxosmithkline Plc, a group of peers worth examining would be IBM, SNY, AZN, DHR, and UTX.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK Stock Price Chart More Charts
GSK Price/Volume Stats
| Current price | $37.89 | 52-week high | $48.25 |
| Prev. close | $37.60 | 52-week low | $31.43 |
| Day low | $37.34 | Volume | 5,204,600 |
| Day high | $38.42 | Avg. volume | 4,949,515 |
| 50-day MA | $41.66 | Dividend yield | 6.3% |
| 200-day MA | $42.65 | Market Cap | 94.55B |
GlaxoSmithKline PLC (GSK) Company Bio
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
GSK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $37.89 | $24.24 | -33% |
We started the process of determining a valid price forecast for Glaxosmithkline Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Glaxosmithkline Plc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 33.17%. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:
- 83% of the company's capital comes from equity, which is greater than 69.41% of stocks in our cash flow based forecasting set.
- The weighted average cost of capital for the company is 7. This value is greater than only 19.91% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -35% |
| 1% | -34% |
| 2% | -33% |
| 3% | -33% |
| 4% | -32% |
| 5% | -32% |
Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See HBIO, HRC, JNJ, CHE, and LHCG.
Top Stories View All
Best & Worst Performing Stock Industries for March 31, 2020
Best & Worst Performing Small Cap Stocks for March 31, 2020
Best & Worst Performing Mid Cap Stocks for March 31, 2020
Best & Worst Performing Large Cap Stocks for March 31, 2020
Best & Worst Performing Mega Cap Stocks for March 31, 2020
View All Top Stories
Loading social stream, please wait...